TFF Pharmaceuticals, Inc. (0K3.F)
| Previous Close | 5.45 |
| Open | 5.30 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 5.30 - 5.30 |
| 52 Week Range | 3.76 - 8.90 |
| Volume | |
| Avg. Volume | 15 |
| Market Cap | 134.471M |
| Beta (5Y Monthly) | 2.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.02 |
| Earnings Date | Mar 08, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Simply Wall St.
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Is Expected To Breakeven In The Near Future
TFF Pharmaceuticals, Inc. ( NASDAQ:TFFP ) is possibly approaching a major achievement in its business, so we would like...
- GlobeNewswire
TFF Pharmaceuticals to Participate at The JMP Securities Life Sciences Conference
FORT WORTH, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the JMP Securities Life Sciences Conference being held June 15 – 16, 2022 at the Lotte New York Palace in New York City. Company management will also
- GlobeNewswire
TFF Pharmaceuticals to Participate at the Jefferies Healthcare Conference
FORT WORTH, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the Jefferies Healthcare Conference being held June 8 – 10, 2022 in New York City. Company management will also be participating in one-on-one meeting
